

BIND Therapeutics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 05-Aug-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

 Phase 2 Clinical..... 11

 Discovery..... 17

[Return to Table of Contents](#)

BIND Therapeutics Inc

COMPANY OVERVIEW

Company Name	BIND Therapeutics Inc
Parent Company Name	BIND Therapeutics Inc
Website	http://www.bindtherapeutics.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	1
Number of Patents as Owner	17
Number of Patents as Third Party	0
Number of Deals	9
Key Indications	Cancer,Breast tumor,Prostate tumor,Non-small-cell lung cancer,Inflammatory disease,Metastatic prostate cancer,Cardiovascular disease,Solid tumor,Asthma,Crohns disease,Dermatitis,Inflammatory bowel disease,Lung tumor,Pancreas tumor,Renal cell carcinoma,Ulcerative colitis
Key Target-based Actions	Glutamate carboxypeptidase II inhibitor,Prostate specific antigen modulator,Aurora protein kinase 1 inhibitor,Unspecified protein kinase inhibitor,Abl tyrosine kinase inhibitor,Integrin alpha-V/beta-3 modulator,mTOR inhibitor,Bcr protein inhibitor,CD40 ligand,DDR tyrosine kinase receptor inhibitor,Epidermal growth factor ligand,Estrogen receptor agonist,Flt3 tyrosine kinase inhibitor,GM-CSF ligand,Insulin-like growth factor ligand,Interleukin-2 ligand,PDGF ligand,Somatostatin ligand
Key Technologies	Nanoparticle formulation,Small molecule therapeutic,Nanoparticle formulation injectable,Intravenous formulation,Quick release formulation,Emulsion formulation,Controlled release formulation,Formulation preservation,Suspension,PEGylated formulation

COMPANY PROFILE

SUMMARY

BIND Therapeutics (previously BIND Biosciences Inc), founded in 2006, is a biopharmaceutical company specializing in the development of therapeutic targeted nanoparticles. In April 2013, BIND Biosciences changed its name to BIND Therapeutics.

LOCATION

The company is headquartered in Boston, MA. It also has a subsidiary office in Moscow region, Russia.

R&D GRANTS

In October 2007, the National Institutes of Standards and Technology awarded BIND a 3-year \$2 million grant to further develop a high-throughput platform for its targeted nanoparticle technology.

Also in October 2007, the NCI awarded BIND a 6-month, \$0.15 million Phase I SBIR grant to develop a targeted therapy for hormone refractory prostate cancer.

FINANCIAL

In December 2013, BIND was added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap Indices.

In October 2013, the company raised \$5.6 million when the underwriters exercised their option to purchase an additional 370,499 shares.

In August 2013, BIND filed a Form S-1 with the US SEC for a proposed IPO. In September 2013, BIND priced an IPO of 4.7 million common stock shares at \$15.00 per share, with trading of the shares to begin on NASDAQ Global Select

[Return to Table of Contents](#)



Market under ticker symbol 'BIND' on September 20, 2013. The underwriters were granted 30-day option to purchase up to 705,000 additional common stock shares; at that time, the offering was expected to close on September 25, 2013. In September 2013, the offering was closed and the company raised the gross proceeds of \$70.5 million.

In October 2011, BIND secured total proceeds of \$47.25 million through a \$22 million series D financing from RUSNANO and additional funding up to \$25.25 million from its investors.

In June 2010, the company secured \$12.4 million in a series C-1 financing.

In January 2010, the company secured \$11 million in a series C financing.

In November 2007, BIND was to raise \$16 million from a series B financing. The funding would be used to advance the company's preclinical pipeline to clinical trials.

EARLY R&D/TECHNOLOGY UPDATES

IND's Medicinal Nanoengineering platform aims to produce targeted nanoparticles with unprecedented control over drug properties to maximize trafficking to disease sites, leading to superior efficacy while minimizing toxicities.


By December 2007, BIND had been focusing on nanoparticles-targeting therapeutic for cancer, cardiovascular diseases and inflammatory diseases; in June 2010, the company planned to advance its second product into clinical development in 2011.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	1	4
Inflammatory disease	1	0	1
Respiratory disease	1	0	1
Genitourinary disease	1	0	1
Cardiovascular disease	1	0	1
Andrology	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	4
Discontinued	1

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	1	0	0	0	1
Drug - Funding	2	0	0	0	2
Drug - Development/Commercialization License	2	0	0	0	3
Patent - Exclusive Rights	0	0	3	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	2	3
Genitourinary disease	1	1
Respiratory disease	1	1
Andrology	1	1

Trials by Phase

Phase	Ongoing	All
Phase 2	2	2
Phase 1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	8	0	8
Gastrointestinal disease	5	0	5
Genitourinary disease	10	0	10

[Return to Table of Contents](#)



Hematological disease	4	0	4
Andrology	8	0	8
Immune disorder	4	0	4
Musculoskeletal disease	2	0	2
Neoplasm	12	0	12
Ocular disease	1	0	1
Neurological disease	4	0	4
Respiratory disease	6	0	6
Infectious disease	2	0	2
Inflammatory disease	2	0	2
Gynecology and obstetrics	9	0	9
Dermatological disease	2	0	2

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics

polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics SNAPSHOT

Drug Name	polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics
Key Synonyms	
Originator Company	BIND Therapeutics Inc
Active Companies	BIND Therapeutics Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Non-small-cell lung cancer;Metastatic prostate cancer;Cancer
Target-based Actions	Prostate specific antigen modulator;Glutamate carboxypeptidase II inhibitor
Other Actions	Microtubule inhibitor;Cell cycle inhibitor
Technologies	Nanoparticle formulation injectable;Intravenous formulation;Small molecule therapeutic
Last Change Date	09-May-2014

polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics DEVELOPMENT PROFILE

SUMMARY

BIND Therapeutics (previously BIND Biosciences) is developing an Accurin, BIND-014, an iv polymeric nanoparticle formulation containing docetaxel, which targets prostate-specific membrane antigen upregulated in solid tumors, developed using the company's Medicinal Nanoengineering platform, for the potential treatment of cancer, including NSCLC and prostate cancer,,,. In April 2013, a phase II trial for NSCLC was initiated. By July 2013, a phase II trial for metastatic castrate resistant prostate cancer had been initiated. In March 2014, the company expected to complete the phase II trials in NSCLC and metastatic castrate resistant prostate cancer in 2014.


polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
BIND Therapeutics Inc	Metastatic prostate cancer	US	Phase 2 Clinical	29-Jul-2013
BIND Therapeutics Inc	Non-small-cell lung cancer	US	Phase 2 Clinical	30-Apr-2013
BIND Therapeutics Inc	Cancer	US	Phase 1 Clinical	07-Jan-2011

[Return to Table of Contents](#)

polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics **CHEMICAL STRUCTURES**

CAS Registry Number:	Confidence Level:
114977-28-5	1
	
Name	Type
docetaxel	INN; USAN
Monotaxel	Trade Name
PEG-TX1	Trade Name
Tyxan	Trade Name
Taxotere	Trade Name
SD-009	Research Code
RP-56976	Research Code
ATI-1123	Research Code
MBP-Y004	Research Code
NKTR-105	Research Code
SYP-0704A	Research Code
CRLX-288	Research Code
BIND-014	Research Code
ML-061	Research Code
NMR-1827	Research Code
SP-1012C	Research Code
docetaxel-PM	
docetaxel-PNP	

[Return to Table of Contents](#)

polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics DRUG NAMES

Names	Type
BIND-014	Research Code
polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics	

polymeric nanoparticle docetaxel (Accurin, solid tumors), BIND Therapeutics CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Non-small-cell lung cancer											
0	0	0	0	1	1	0	0	0	0	1	1
Metastasis											
0	0	0	0	0	0	0	1	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	0	1	0	0	1	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
BIND Therapeutics Inc	2	0	3	0	5
Yale University	1	0	0	0	1
US Government	0	0	1	0	1
National Institutes of Standards and Technology	0	0	1	0	1
Massachusetts Institute of Technology	1	0	0	0	1
Johns Hopkins University	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Patent - Exclusive Rights	3	0	3
Drug - Funding	2	0	2

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
BIND Therapeutics Inc	4	0	4
Individual	3	0	3

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	4
Product	1
New use	1

AZD1152-hQPA Accurins (nanoparticle, cancer), Astrazeneca/BIND

AZD1152-hQPA Accurins (nanoparticle, cancer), Astrazeneca/BIND SNAPSHOT

Drug Name	AZD1152-hQPA Accurins (nanoparticle, cancer), Astrazeneca/BIND
Key Synonyms	
Originator Company	BIND Therapeutics Inc
Active Companies	AstraZeneca plc;BIND Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Aurora protein kinase 1 inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Nanoparticle formulation;Small molecule therapeutic
Last Change Date	09-May-2014

AZD1152-hQPA Accurins (nanoparticle, cancer), Astrazeneca/BIND DEVELOPMENT PROFILE

SUMMARY

BIND Therapeutics and AstraZeneca are investigating Accurin nanoparticle formulation of AstraZeneca's barasertib metabolite, AZD1152-hQPA (structure shown), developed using BIND's Accurin technology, for the potential treatment of cancer. By April 2013, a feasibility program had been completed. At that time, IND-enabling studies were ongoing. In April 2014, preclinical data were presented.


AZD1152-hQPA Accurins (nanoparticle, cancer), Astrazeneca/BIND DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
AstraZeneca plc	Cancer	UK	Discovery	22-Apr-2013
BIND Therapeutics Inc	Cancer	US	Discovery	22-Apr-2013

AZD1152-hQPA Accurins (nanoparticle, cancer), Astrazeneca/BIND CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
AZD-1152-hydroxyQPA	Metabolite
AZD-1152-hQPA	Metabolite


AZD1152-hQPA Accurins (nanoparticle, cancer), AstraZeneca/BIND DRUG NAMES

Names	Type
AZD-1152-hQPA	Metabolite
kinase inhibitor (Accurin nanomedicine, cancer), BIND Therapeutics/ AstraZeneca	
AZD-1152-hydroxyQPA	Metabolite
AZD1152-hQPA Accurins (nanoparticle, cancer), AstraZeneca/BIND	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
AstraZeneca plc	0	0	1	0	1
BIND Therapeutics Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics

molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics SNAPSHOT

Drug Name	molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics
Key Synonyms	
Originator Company	BIND Therapeutics Inc
Active Companies	BIND Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	
Other Actions	Anticancer
Technologies	Nanoparticle formulation;Small molecule therapeutic
Last Change Date	08-Apr-2013

molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics DEVELOPMENT PROFILE

SUMMARY

BIND Therapeutics (previously BIND Biosciences) is investigating Accurins as molecularly-targeted therapeutics, including chemotherapeutics, using the company's Medicinal Nanoengineering platform, for the potential treatment of cancer,. In September 2012, the program was listed as being in lead optimization. In April 2013, development was ongoing.

molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
BIND Therapeutics Inc	Cancer	US	Discovery	11-Sep-2012

molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics DRUG NAMES

Names	Type
molecularly-targeted Accurins (nanoparticle formulation, cancer), BIND Therapeutics	
Accurin cytotoxics (nanoparticle formulation, cancer), BIND Therapeutics	
Accurin chemotherapeutics (nanoparticle formulation, cancer), BIND Therapeutics	

[Return to Table of Contents](#)



targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics

targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics SNAPSHOT

Drug Name	targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics
Key Synonyms	
Originator Company	BIND Therapeutics Inc
Active Companies	BIND Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease
Target-based Actions	
Other Actions	Anti-inflammatory;Unspecified drug target
Technologies	Nanoparticle formulation;Small molecule therapeutic
Last Change Date	03-Apr-2013

targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics DEVELOPMENT PROFILE

SUMMARY

BIND Therapeutics (previously BIND Biosciences) is investigating Accurins as targeted nanoparticle formulation, developed using the company's Medicinal Nanoengineering platform, for the potential treatment of inflammatory diseases, including conditions involving chronic inflammation, such as arthritis and inflammatory bowel disease,. In September 2012, the program was listed as being in lead optimization.

targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
BIND Therapeutics Inc	Inflammatory disease	US	Discovery	12-Jan-2010

targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics DRUG NAMES

Names	Type
targeted Accurins (nanoparticle formulation, inflammatory disease), BIND Therapeutics	

[Return to Table of Contents](#)

targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics

targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics SNAPSHOT

Drug Name	targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics
Key Synonyms	
Originator Company	BIND Therapeutics Inc
Active Companies	BIND Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cardiovascular disease
Target-based Actions	
Other Actions	Unspecified drug target;Cardiovascular agent
Technologies	Nanoparticle formulation;Small molecule therapeutic
Last Change Date	03-Apr-2013

targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics DEVELOPMENT PROFILE

SUMMARY

BIND Therapeutics (previously BIND Biosciences) is investigating Accurins as targeted nanoparticle formulation, developed using the company's Medicinal Nanoengineering platform, for the potential treatment of cardiovascular disease. In August 2011, preclinical studies were ongoing; in September 2012, the program was listed as being in discovery.

targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
BIND Therapeutics Inc	Cardiovascular disease	US	Discovery	12-Jan-2010

targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics DRUG NAMES

Names	Type
targeted Accurins (nanoparticle formulation, cardiovascular disease), BIND Therapeutics	

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

